Elicio Therapeutics, Inc. · NASDAQ:ELTX
Elicio Therapeutics — Investor Presentation (May 2025)
52 slides from Elicio Therapeutics's investor presentation, May 2025
Slide 1: Targeting the Lymph Nodes to AMPlify Immunotherapy
Targeting the Lymph Nodes to AMPlify Immunotherapy Nasdaq: ELTX May 2025
Slide 2: Disclaimers
Disclaimers No Representation or Warranty We do not make and hereby expressly disclaim any representation or warranty, express or implied, as to the reasonableness of the assumptions made in the Presentation or the accuracy or completeness or the information contained in or incorporated by reference
Slide 3: Disclaimers
Disclaimers Forward-Looking Statements This presentation contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, kno
Slide 4: Investment Highlights
Investment Highlights Clinical-stage Biotech Developing Novel Lymph Node-targeted “off the shelf” Cancer Immunotherapies • Our proprietary AMP platform is designed to generate robust, functional, and durable immune responses by Leveraging proprietary targeting lymph nodes • AMP technology delivers a
Slide 5: Seasoned Management Team
Seasoned Management Team Robert Connelly Peter DeMuth, PhD Christopher Haqq, MD, PhD Preetam Shah, MBA, PhD Megan Filoon, JD Chief Executive Officer Chief Scientific Officer Executive Vice President, Head Chief Strategy and Financial General Counsel, Secretary and of Research and Development, Office
Slide 6: Company Pipeline
Company Pipeline Innovative Pipeline of Cancer Immunotherapies Addressing Critical Unmet Needs Candidate Target Indication Setting Preclinical IND Ready Phase 1 Phase 2 Phase 3 ELI-002 mKRAS PDAC Adjuvant ELI-002 mKRAS CRC Adjuvant ELI-002 mKRAS CRC Metastatic ELI-002 Neoadjuvant mKRAS PDAC IIT + CP
Slide 7: The Addressable KRAS-mutant Market – A Significant Opportunity
The Addressable KRAS-mutant Market – A Significant Opportunity ELI-002 Targets the 7 Most Common KRAS Mutations Driving 25% of Solid Tumors Pancreatic Ductal Non-Small Cell Lung Other mKRAS Colorectal Cancer Adenocarcinoma Cancer Opportunities ELI-002 addressable ELI-002 addressable ELI-002 addressa
Slide 8: Significant Opportunity to Treat Multiple Common Cancers with KRAS Mutations
Significant Opportunity to Treat Multiple Common Cancers with KRAS Mutations Mutant KRAS Drives 25% of Solid Human Cancers Pancreatic Ductal Adenocarcinoma (PDAC) Prevalent among numerous tumor types US Incidence: ~56k Colorectal Cancer (CRC) Overall poor clinical prognosis US Incidence: 151k Limite
Slide 9: ELI-002’s Differentiated Approach to mKRAS Therapy
ELI-002’s Differentiated Approach to mKRAS Therapy Validated mKRAS Target | Differentiated Vaccine Approach | Advanced Clinical Stage Small Molecules Personalized Cancer Vaccines Targeting Lymph Node Targeted Vaccine Targeting Inhibiting Mutant KRAS Private Tumor Neoantigens Mutant KRAS FDA approval
Slide 10: Amphiphile (AMP) Platform
Targeting the Lymph Nodes to Orchestrate Immunity Amphiphile (AMP) Platform
Slide 11: Amphiphile (AMP) Platform Enables Lymph Node Delivery with Simple and Versatile Application
Amphiphile (AMP) Platform Enables Lymph Node Delivery with Simple and Versatile Application AMP: A Modular Chemical Conjugation Approach for Delivery of Immune Therapeutics to the Lymph Nodes Small Molecules Peptides Nucleic Payload Acids Proteins 1 Albumin Binding Lipid 2 Polymeric Linker 3 Payload
Slide 12: MOA: Targeting the Lymph Nodes with AMP to Orchestrate Immunity
MOA: Targeting the Lymph Nodes with AMP to Orchestrate Immunity Tissue Injection Site Lymph Node AMP Endogenous Albumin Albumin-bound AMP APC Activation T / B Cell Response • Expansion • Persistence • Effector function • Phenotype Albumin-bound AMP Antigen Presenting Cell T Cell B Cell Subcutane
Slide 13: AMP-vaccination Induces Coordinated Immune Activation in Lymph Nodes
AMP-vaccination Induces Coordinated Immune Activation in Lymph Nodes Enhanced Antigen-specific T cell Response Magnitude and Functional Quality Albumin-based Delivery to Lymph Nodes Blood IFNγ+ T Cell Response gp100 Antigen Albumin Soluble AMP (65 kDa) 2% 52% IFN-γ Binding to Tissue Albumin CD8 Enha
Slide 14: ELI-002 2 Peptide (2P) Formulation
Boosting Endogenous Anti-tumor Immunity Targeting mKRAS ELI-002 2 Peptide (2P) Formulation
Slide 15: ELI-002 Is a Lymph Node Targeted mKRAS Vaccine
ELI-002 Is a Lymph Node Targeted mKRAS Vaccine Proprietary AMP-CpG Adjuvant Shown to Enhance Immunogenicity in Early-Stage Trials ELI-002 G12X Peptide 2P D R Composition AMP-mKRAS X X Peptide Antigen ELI-002 • 2 or 7 AMP-peptides • CD8 and CD4 epitopes Albumin Binding Lipid for Lymph PEG Linker mKRA
Slide 16: ELI-002 2P Phase 1 Study Overview
ELI-002 2 Peptide Phase 1 Study Overview *Published in Nature Medicine ELI-002 2P Phase 1A Phase 1 adjuvant dose-ranging study to assess safety and efficacy of ELI-002 2P in patients who completed standard therapy and have molecular disease ELI-002 MONOTHERAPY: NCT04853017 Monotherapy (no chemo, CPI
Slide 17: ELI-002 2P Induces Tumor Biomarker Declines in Majority of Phase 1a Patients
ELI-002 2P Induces Tumor Biomarker Declines in Majority of ELI-002 2P Phase 1A Phase 1a Patients Robust responses observed across tumor types and KRAS mutations with ELI-002 monotherapy Tumor Biomarker Responses ELI-002 2P Waterfall Plot: Biomarker Reduction/Clearance Best Overall Biomarker Response
Slide 18: ELI-002 Elicits Robust Immune Responses in Majority of Phase 1a Patients
ELI-002 Elicits Robust Immune Responses in Majority of ELI-002 2P Phase 1A Phase 1a Patients 84% of patients generated mKRAS-specific T cells directly ex vivo; 100% at RP2D ELI-002 2P T Cell Fold-Changes mKRAS T Cell Responses Direct Ex Vivo T Cell Response 450 0.1 mg • T cells detectable by standar
Slide 19: ELI-002 2P: T Cell Response Magnitude Correlates with Tumor Biomarker Response
ELI-002 2P: T cell Response Magnitude Correlates with Tumor ELI-002 2P Phase 1A Biomarker Response All patients with T cell responses over the median showed tumor biomarker response mKRAS T Cell Response Tumor Biomarker Response Best Overall Tumor Biomarker Response Clearance Reduction Non-Responder
Slide 20: ESMO-IO Update: RFS in Full Cohort vs PDAC Subgroup
ELI-002 2P Phase 1A ESMO-IO UPDATE: RFS in Full Cohort vs PDAC Subgroup Median follow up has increased to 19.7 months vs 8.5 months in Pant et al., 2024 Nature Med Median RFS times similar for the full cohort and PDAC subgroup: Data cut-off Sept 24, 2024 Relapse-free Survival: Full Cohort (n=25) Rel
Slide 21: 2024 ESMO-IO Update Shows Strong Correlation between RFS and T Cell Response
2024 ESMO-IO Update Shows Strong Correlation between RFS ELI-002 2P Phase 1A and T Cell Response RFS Prolonged - no relapse or death in 10/13 (77%) of above median T cell group Relapse-free Survival: DCO September 24, 2024 ELI-002 2P Relapse-free Survival DCO 06-Sept-2023 24-Sept-2024 Median RFS: No
Slide 22: 2024 ESMO-IO Update Shows Early Encouraging Patient Survival
ELI-002 2P Phase 1A 2024 ESMO-IO Update Shows Early Encouraging Patient Survival Full Cohort (n=25) Overall Survival; mOS 28.94 months is longer than historical for PDAC, CRC not yet estimable Overall Survival: DCO September 24, 2024 ELI-002 2P Relapse-free and Overall Survival Cohort Full (n=25) PD
Slide 23: ELI-002 Summary of Phase 1 Clinical Trials
ELI-002 Summary of Phase 1 Clinical Trials 39 patients treated in two Phase 1A trials: ELI-002 2P and ELI-002 7P • MRD+ PDAC (n=33) and CRC (n=6) patients treated after local surgery and chemotherapy (adjuvant setting) • Phase 1 trials included dose-ranging for both peptide and adjuvant components o
Slide 24: ELI-002 7P: Phase 1a Trial of 7-Peptide Formulation
Enhancing Endogenous Anti-tumor Immunity by Using Additional Peptides Targeting mKRAS ELI-002 7P: Phase 1a Trial of ELI-002 7-Peptide Formulation First-in-human Study: mKRAS G12x or G13D-expressing, Adjuvant treatment of MRD+ PDAC and CRC
Slide 25: ELI-002 Is a Lymph Node Targeted mKRAS Vaccine
ELI-002 Is a Lymph Node Targeted mKRAS Vaccine Proprietary AMP-CpG Adjuvant Shown to Enhance Immunogenicity in Early-Stage Trials ELI-002 G12X G13X Peptide 7P D R V C S A D Optimization of Composition AMP-Peptide Dose AMP-mKRAS X X Peptide Antigen ELI-002 • 2 or 7 AMP-peptides • CD8 and CD4 epitopes
Slide 26: ELI-002 7P Phase 1A Study Overview
ELI-002 7P Phase 1A ELI-002 7P Phase 1A Study Overview Phase 1 peptide dose-ranging study to assess safety and efficacy of ELI-002 7P in patients who completed standard therapy and have minimal residual disease ELI-002 MONOTHERAPY: NCT05726864 Monotherapy (no chemo, CPI combo) Complete Local Therapy
Slide 27: ELI-002 7P Elicits Immune Responses in all Phase 1a Patients
ELI-002 7P Elicits Immune Responses in all Phase 1a Patients ELI-002 7P Phase 1A 100% of patients with robust T cell response mKRAS T Cell Responses ELI-002 7P T Cell Fold-Changes by Dose Level • 100% of patients showed T cell responses Direct Ex Vivo T Cell Response Dose T Cell Response • 4.9 mg do
Slide 28: ELI-002 7P: T Cell Response Magnitude Correlates with Dose
ELI-002 7P: T Cell Response Magnitude Correlates with Dose ELI-002 7P Phase 1A Phase 2 Dose generates higher immune response than seen with ELI-002 2P ELI-002 2P vs ELI-002 7P 4.9 mg ELI-002 2P ELI-002 7P ELI-002 7P (Nat Med) (All) (4.9 mg) • ELI-002 7P data based on n=12 Patients (1.4 mg, n=5; 4.9
Slide 29: ELI-002 7P: ELI-002 Stimulates Antigen Spreading
ELI-002 7P: ELI-002 Stimulates Antigen Spreading ELI-002 7P Phase 1A Expansion of T cells specific to personalized tumor antigens not targeted by vaccination Antigen Spreading to Personal Tumor Neoantigens Immunogenic Non-immunogenic 10 • ELI-002 7P vaccination led to expansion of T cell responses t
Slide 30: ELI-002 7P Induces Tumor Biomarker Declines in Majority of Patients
ELI-002 7P Induces Tumor Biomarker Declines in Majority of ELI-002 7P Phase 1A Phase 1A Patients Waterfall reflects superiority of 4.9 mg AMP-Peptide 7P dose level Tumor Biomarker Responses ELI-002 7P Waterfall Plot: Biomarker Reduction / Clearance * 100 Amph-Peptides-7P Dose • 71% (5/7) of patients
Slide 31: ELI-002 7P: T Cell Response Drives Tumor Biomarker Response
ELI-002 7P: T Cell Response Drives Tumor Biomarker Response ELI-002 7P Phase 1A All patients with T cell responses above median showed tumor biomarker response mKRAS T Cell Response Tumor Biomarker Response Best Overall Tumor Biomarker Response Clearance Reduction Non-Responder • Strength of T cell
Slide 32: ELI-002 7P: DFS Strongly Correlates with T Cell Response
ELI-002 7P: DFS Strongly Correlates with T Cell Response ELI-002 7P Phase 1A Improved DFS associated with above median T cell response ELI-002 7P Disease-free Survival Supervised by Median T cell Fold Change 6 mo 12 mo • Induction of above median mKRAS-specific T cell responses by ELI-002 7P associa
Slide 33: ELI-002 7P: Safety
ELI-002 7P: Safety ELI-002 7P Phase 1A ELI-002 was well tolerated at all dose levels with no DLTs observed ELI-002 7P Safety / Tolerability ELI-002 7P Dose 1.4 mg 4.9 mg Overall n=6 n=8 n=14 • No DLT observed, No CRS or T cell Toxicities Adverse Event Term a Patients with Any Related TEAE, • Most co
Slide 34: Enrollment Complete for ELI-002 Randomized Phase 2 PDAC
ELI-002 7P Phase 2 Enrollment Complete for ELI-002 Randomized Phase 2 PDAC Event Driven Interim DFS Analysis Expected Q3 2025 for 2:1 Randomized, Open Label Study CLINICAL STUDY OVERVIEW: NCT05726864 Monotherapy (no chemo, CPI combo) Schema Endpoints mKRAS: Expanded Antigen Coverage Primary Endpoi
Slide 35: Other Pipeline Assets
Other Pipeline Assets
Slide 36: ELI-007 (BRAF) and ELI-008 (p53)
ELI-007 (BRAF) and ELI-008 (p53) Designing an AMP-Vaccine Targeting Mutant BRAF and p53 ELI-007 ELI-008 Mutant % Patients Mutant % Patients AMP-BRAF AMP-p53 1 V600E ~90% 1 R248W 3.53% Peptide Antigen Peptide Antigen 2 V600K ~5% 2 R248Q 4.37% 3 R175H 5.60% • 2 AMP-peptides • Up to 12 AMP-peptides 4 R
Slide 37: ELI-007: Why Target mutant BRAF with Vaccine Therapy?
ELI-007: Why Target mutant BRAF with Vaccine Therapy? Mutant BRAF is a Common Cancer Driver Mutant BRAF is a Promising Tumor Antigen • Prevalent among numerous tumor types • Truncal: mutations occur early, expressed uniformly in tumor cells • Overall poor clinical prognosis • Limited therapeutic opt
Slide 38: ELI-007 Is a Lymph Node Targeted mBRAF Vaccine
ELI-007 Is a Lymph Node Targeted mBRAF Vaccine AMP-modification enhances BRAF V600E-specific T cell responses Experimental Schema: Mutant Peptide T Cell Response: BRAF V600 Spleen Day 35 BRAF V600E 29-mer BRAF V600K 29-mer Stim: V600E or V600K Peptide Pool Mock T Cells: V600E T Cells: V600K Treatmen
Slide 39: ELI-008: Why Target mutant p53 with Vaccine Therapy?
ELI-008: Why Target mutant p53 with Vaccine Therapy? Mutant p53 Drives ~30% of Human Cancers Mutant p53 is a Promising Tumor Antigen • Prevalent among numerous tumor types • Truncal: mutations occur early, expressed uniformly in tumor cells • Limited therapeutic options • Driver: mp53 signaling is r
Slide 40: ELI-008 Is a Lymph Node Targeted mp53 Vaccine
ELI-008 Is a Lymph Node Targeted mp53 Vaccine AMP-modification enhances p53 hot-spot mutant-specific T cell responses Experimental Schema: Mutant Peptide T Cell Response: p53 Spleen Day 35 p53 R248Q 30-mer p53 R20175H 30-mer Stim: p53 R248Q, R175H, or R273H OLPs p53 R273H 30-mer Mock Treatment T Cel
Slide 41: ELI-004: AMP-CpG Combination with Radiation to Induce Tumor-specific Immunity In Situ
ELI-004: AMP-CpG Combination with Radiation to Induce Tumor-specific Immunity In Situ Tumor Lymph Node Tumor AMP- CpG Tumor Antigen + AMP-CpG Uptake Tumor Cell Killing Releases Additional Tumor Antigen Release Antigen Presenting Cell T Cells Antigen into Lymph Nodes Local Therapy Radiation + Tumor C
Slide 42: Key Milestones Achieved and Growth Initiatives for 2025
Key Milestones Achieved and Growth Initiatives for 2025 ELI-002 Clinical Development 2025 Growth Initiatives Preliminary Phase 1 T Cell and biomarker response (ASCO) Initiate ELI-002 + CPI investigator-sponsored clinical combination study in neo-adjuvant PDAC and potential other ELI-002 combinat
Slide 43: Investment Highlights
Investment Highlights Clinical-stage biotech developing novel lymph node-targeted “off the shelf” cancer immunotherapies • Our proprietary AMP platform is designed to generate robust, functional, and durable immune responses by Leveraging proprietary targeting lymph nodes • AMP technology delivers a
Slide 44: Appendix
Appendix
Slide 45: H2 2024 Execution
H2 2024 Execution Phase 2 trial fully enrolled – 144 patients enrolled in 11 months in 27 clinical sites • $33M in new capital raised – expected to fund the Company into Q2 2025 beyond the anticipated Phase 2 interim analysis • ELI-002 7P updated Phase 1a data presented at AACR-Special Conference-Pa
Slide 46: AMP Platform Technology
AMP Platform Technology Cancer Vaccines Versatile | Simple | Clinical Stage Immunotherapy / Combinations 2014 Liu Nature 2016 Moynihan Nature Medicine CAR-T Cell Adoptive Therapy 2018 Moynihan Cancer Immunology Research Applications 2019 Ma Science TCR-T Cell Adoptive Therapy 2021 Rakhra Science Imm
Slide 47: “Albumin-hitchhiking” Reprograms Delivery of Vaccines and Immunotherapy to Target Lymph Nodes
“Albumin-hitchhiking” Reprograms Delivery of Vaccines and Immunotherapy to Target Lymph Nodes Tissue Injection Site: Molecular Size Determines Distribution Albumin-based Delivery to Lymph Nodes Blood Vessel Albumin (65 kDa) Blood Blood Systemic Circulation Systemic Circulation Poor Delivery Reduced
Slide 48: The AMP Platform Technology
Designing a system to target vaccines to Lymph Nodes: The AMP Platform Technology
Slide 49: AMP-vaccines Target the Lymph Nodes for Efficient Uptake by Resident Antigen Presenting Cells
AMP-vaccines Target the Lymph Nodes for Efficient Uptake by Resident Antigen Presenting Cells Soluble CpG AMP CpG AMP CpG Lymph Node Delivery Schema CpG CpG CpG T cells B cells T cells B cells Macrophage DC Assay Lymph Node Uptake Hours 0 24 Dose Lymph Node Retention Lymph Node Lymph Node Colocaliza
Slide 50: AMP-vaccination Induces Coordinated Immune Activation in Lymph Nodes
AMP-vaccination Induces Coordinated Immune Activation in Lymph Nodes Comprehensive inflammatory transcriptional reprogramming Lymph Node Transcriptomics: 24 hours Mock Soluble AMP MYD88 IFIH1 DDX58 Mock Subtracted Unchanged Pattern Recognition ZBP1 Ifi204 Average Z-score, 3 MARCO p < 0.05 -log 10 (p
Slide 51: AMP-vaccination Induces Coordinated Immune Activation in Lymph Nodes
AMP-vaccination Induces Coordinated Immune Activation in Lymph Nodes Inflammatory proteomic signatures and coordinated innate cell recruitment and activation Lymph Node Proteomics 24 hours Lymph Node Cell Dynamics 24 hours Mock Soluble AMP Mock Soluble AMP Mock Subtracted ** **** Growth G-CSF IFN γ
Slide 52: AMP-vaccination Induces Coordinated Immune Activation in Lymph Nodes
AMP-vaccination Induces Coordinated Immune Activation in Lymph Nodes Enhanced antigen-specific T cell response magnitude and functional quality AMP Vaccine Platform Blood IFNγ+ T Cell Response gp100 Antigen Soluble AMP 2% 52% Enhanced Lymph Node Delivery and Retention IFN-γ CD8 Increased Uptake into
Elicio Therapeutics — Investor Presentation (May 2025) on 6ix